Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021PRNewsWire • 11/08/21
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry DiseasePRNewsWire • 10/15/21
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry DiseasePRNewsWire • 10/11/21
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business UpdatePRNewsWire • 08/16/21
Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021PRNewsWire • 08/09/21
Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate ApplicationBenzinga • 08/02/21
Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDAPRNewsWire • 08/02/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLXNewsfile Corp • 06/06/21
Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102Benzinga • 06/02/21
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry DiseasePRNewsWire • 06/02/21
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business UpdatePRNewsWire • 05/14/21
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021PRNewsWire • 05/07/21
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDAPRNewsWire • 04/28/21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDAPRNewsWire • 04/28/21